Faldaprevir and pegylated interferon alpha-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV
Publication Type:
Journal Article
Authors:
D. Dieterich;
Nelson, M.;
Soriano, V.;
Arasteh, K.;
Guardiola, J.M.;
J K Rockstroh;
Bhagani, S.;
Laguno, M.;
Tural, C.;
Ingiliz, P.;
Jain, M.K.;
Stern, J.O.;
Manero, M.;
Vinisko, R.;
Kort, J.;
STARTVerso4 study groupSource:
AIDS, Volume 29, Issue 5, p.571-581 (2015)
Keywords:
analysis,
Antiretroviral,
Antiretroviral Therapy,
co-infected,
co-infection,
coinfection,
Connecticut,
efavirenz,
Genotype,
genotype 1,
Germany,
HCV,
hepatitis,
Hepatitis C,
hepatitis C virus,
Hiv,
interferon,
Liver,
Liver Cirrhosis,
London,
Medicine,
methods,
Multivariate Analysis,
New York,
pegylated,
pegylated interferon,
protease inhibitor,
Rna,
Safety,
Spain,
sustained virologic response,
SVR,
Texas,
therapy,
treatment,
treatment-naive
